Table of Contents
- 01Introduction
- 02What Project Orbis Actually Does
- 03Why Oncology Specifically
- 04What Changes for Regulatory Teams
- 05What a Typical Review Cycle Looks Like
- 06How This Differs From Mutual Recognition or Reliance Pathways
- 07How Sponsors Decide Whether to Pursue It
- 08Limitations Worth Understanding
- 09What This Means for Hiring
- 10Conclusion
Introduction
A sponsor that wants to launch an oncology drug in several countries has traditionally had to run several separate review processes, each with its own dossier format, review timeline, and set of questions from health authority reviewers. Project Orbis, the FDA Oncology Center of Excellence initiative that coordinates simultaneous review of promising cancer therapies among a group of partner regulatory agencies, was built to shorten that process without lowering the bar for approval. It has quietly become one of the more consequential pieces of regulatory infrastructure in oncology drug development, and it has reshaped how regulatory teams plan global submission strategy for cancer therapies with strong early clinical data.
What Project Orbis Actually Does
Project Orbis is a framework, not a single joint approval. A sponsor submits an application to FDA and, in parallel, to one or more of the partner agencies that have joined the initiative, which includes authorities such as Australia's Therapeutic Goods Administration, Health Canada, the UK's Medicines and Healthcare products Regulatory Agency, Switzerland's Swissmedic, Singapore's Health Sciences Authority, and Brazil's ANVISA, among others that have joined since the program launched. Each agency still conducts its own independent review and reaches its own decision under its own legal authority. What Project Orbis changes is the choreography: the participating agencies review the same data package on an overlapping timeline, hold joint or near-simultaneous discussions with the sponsor, and share review findings and questions with each other where their laws permit, rather than each agency starting its clock only after the others have finished. For a drug with genuinely practice-changing early data, that compressed, coordinated timeline can mean patients in multiple countries gaining access to a new therapy within months of each other instead of years apart.
168 open now
Regulatory affairs roles
Senior Regulatory Affairs Consultant - Regulatory Project ManagerParexelRemote, US
Senior Director, Regulatory Strategy Leader-OncologyIQVIADurham, NC$186K–$519K
Global Regulatory Sciences Biopharmaceutical Sector Internship Summer 2027Bristol Myers SquibbPrinceton, NJ
Regulatory Affairs DirectorAstraZenecaCambridge, MA · Hybrid$186K–$279K
Why Oncology Specifically
The program grew out of FDA's existing accelerated pathways for oncology, including breakthrough therapy designation and other expedited programs that already compress the US review timeline for drugs addressing serious unmet need. Project Orbis extends that same logic internationally: cancer therapies with striking early efficacy signals are exactly the cases where a drawn-out, sequential multi-country review process has the highest cost in delayed patient access. Oncology also benefits from a relatively mature set of surrogate endpoints and expedited-review infrastructure that most other therapeutic areas don't share to the same degree, which made it a practical starting point for a multi-agency pilot that has since proven durable enough to keep expanding its partner roster.
What Changes for Regulatory Teams
Participating in Orbis means regulatory affairs and regulatory strategy staff need to plan a genuinely global submission from the start, rather than treating ex-US filings as sequential follow-on work after a US approval. That has several practical effects on how regulatory teams structure their work. Dossier preparation has to anticipate the format and content expectations of multiple agencies simultaneously, even though each participating authority retains its own submission requirements. Regulatory professionals on an Orbis submission often field near-simultaneous information requests from several agencies on compressed timelines, which puts a premium on regulatory operations capacity and on having regional regulatory leads who can represent the program credibly in direct agency interactions, not just route documents. Because the agencies may discuss the application with each other, sponsors also need regulatory staff who understand that a response given to one agency may effectively become visible, in substance, to the others reviewing the same package, which argues for tightly coordinated messaging across the regulatory team rather than country-by-country improvisation.
What a Typical Review Cycle Looks Like
While the specifics vary by program, an Orbis review generally follows a recognizable pattern once a sponsor's application is accepted into the framework. Early in the process, FDA's Oncology Center of Excellence coordinates an initial kickoff where participating agencies and the sponsor align on scope, timelines, and points of contact. As the review proceeds, agencies typically hold joint teleconferences with the sponsor at key milestones rather than conducting entirely separate, siloed interactions, which gives the regulatory team a single forum to address cross-cutting scientific questions instead of fielding the same question five different times through five different channels. Toward the end of the review, agencies often converge on their decisions within a relatively tight window of each other, though exact timing still depends on each authority's own internal process and any country-specific requirements, such as additional data requests unique to a particular market's patient population or standard of care. Regulatory operations staff on these programs describe the experience as more intense but also more transparent than sequential filing, since the sponsor has better visibility into what every reviewing agency is thinking at roughly the same time.
How This Differs From Mutual Recognition or Reliance Pathways
It's worth distinguishing Orbis from reliance-based frameworks where one agency's decision is used by another as the basis for a faster, largely deferential review. Under Orbis, every participating agency performs its own full, independent scientific assessment; none is simply adopting another's conclusion. That means a drug is not guaranteed approval in every participating country just because FDA approves it, and timelines, outcomes, and approved indications have diverged across Orbis partner agencies for the same product in practice. Regulatory teams need to resist treating Orbis as a reliance shortcut and instead continue building the kind of agency-specific scientific and regulatory strategy each jurisdiction's own review division expects, just on a tighter, more coordinated schedule.
How Sponsors Decide Whether to Pursue It
Not every oncology drug is a good candidate for an Orbis submission, and regulatory strategists are typically the ones making the case internally for whether to pursue it. The program tends to suit therapies with striking early efficacy data in a serious or life-threatening cancer, the kind of profile that would already qualify for FDA's expedited pathways domestically, since the whole premise of coordinated review rests on the data being strong enough to justify a compressed timeline across multiple agencies at once. A sponsor also has to weigh its own operational readiness: an Orbis submission demands the regulatory, clinical, and manufacturing teams be prepared to respond to several agencies' questions on overlapping timelines, which is a meaningfully heavier lift than a staggered, country-by-country filing strategy. Companies with thin regulatory affairs bench strength sometimes find that the operational demands of a true multi-agency simultaneous review outweigh the time saved, particularly if their commercial priorities don't require near-simultaneous launch across the participating markets. The decision is as much a resourcing and sequencing question as it is a scientific one.
Limitations Worth Understanding
Orbis has clear boundaries that are easy to overstate in casual conversation about the program. It does not create a single, unified approval; a drug can be approved by FDA and still be rejected, delayed, or approved with a narrower indication by a partner agency reviewing the identical data package, because each regulator applies its own legal standard and risk tolerance. The program also does not reduce the substantive evidentiary bar for approval anywhere, it only changes the choreography and timing of review, so sponsors sometimes discover that participating in Orbis exposes them to tougher, more detailed questioning than they would have faced filing with a single agency alone, since multiple expert review teams are now scrutinizing the same data in parallel. And Orbis participation is not automatic or guaranteed; FDA's Oncology Center of Excellence and the partner agencies decide jointly whether a given program is a fit for the framework, so sponsors need a credible scientific rationale before assuming Orbis is available to them.
What This Means for Hiring
Sponsors running or considering an Orbis submission increasingly look for regulatory affairs professionals with direct multi-region oncology submission experience, not just US-only FDA expertise. Experience managing simultaneous agency interactions, familiarity with the submission and labeling conventions of the specific partner agencies involved, and comfort working across time zones on compressed review clocks are all explicitly called out in job postings for oncology regulatory affairs roles at companies with active or anticipated Orbis programs. This has created real demand for regulatory strategists who have actually sat through an Orbis-coordinated review cycle, since that operational experience is difficult to replicate through general global regulatory affairs background alone. It has also increased the value of regional regulatory leads based outside the United States who can represent a sponsor directly to their home agency while staying synchronized with the broader program team.
Conclusion
Project Orbis is a working example of regulatory agencies choosing coordination over either full harmonization or complete independence, and it has measurably changed how fast some oncology therapies reach patients in multiple countries. For regulatory affairs professionals, it has raised the bar on what global submission planning looks like for high-priority cancer therapies and created real, specific hiring demand for people who can operate across several agencies' expectations at once. It has also pushed oncology regulatory strategy earlier into a program's development timeline, since a sponsor that wants to be ready for an Orbis submission has to be planning its multi-agency regulatory approach well before pivotal data even reads out, rather than treating international filing as something to figure out after a US approval is already in hand. Understanding how the program actually works, where its genuine advantages lie, and where its limits are, is increasingly a practical requirement for anyone building a career in oncology regulatory affairs rather than a niche curiosity.
Regulatory & Quality. REWIRED.
New roles. Real pay. Your next move.
- Hand-picked roles, every week.
- The newest company pages.
- One article worth your time.
Free. Thursday mornings. One-click unsubscribe.
About the author
Connor GriggsMSRA, CQA
Founder & Editor-in-Chief
Connor began his career as a regulatory analyst at the FDA and has spent 13 years in medical device regulatory affairs and quality.
Find your next regulatory or quality role
Every role on Regulatory Jobs is in regulatory, quality or compliance, in pharma, biotech or medical devices. Set an alert and the next one reaches you the day it posts.
